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Purpose: Endovascular mechanical thrombectomy using the AngioJet™ system
can be considered to reestablish patency in occluded vascular access. The aim of
this study was to review our results for endovascular mechanical thrombectomy
using the AngioJet™ system in patients with arteriovenous fistulae (AVF) and
arteriovenous grafts (AVG).
Methods: Data collected in a database of patients requiring hemodialysis for renal
failure were analyzed. Patients who underwent endovascular mechanical
thrombectomy procedures with the AngioJet™ system for occlusion of
vascular access were included. Clinical and technical success rates and patency rates
were calculated. Multivariate analysis was used to identify factors of influence.
Results: A total of 92 AngioJet™ procedures in 60 patients with thrombosed vascular
access were reviewed during a mean follow-up period of 21.5 months in patients
with an AVF and 11.9 months in patients with an AVG. Technical and clinical success
was achieved in 92.6% of AVF cases and 92.0 and 90.8% of AVG cases with an AVG,
respectively. Significantly higher primary and primary-assisted patency rates were
observed in the AVF group. Multivariate regression analysis indicated that left-sided
vascular access and female sex were independent predictors for failure regarding pri-
mary patency in AVG patients. Immunosuppressive drugs and older age were nega-
tive predictors for secondary patency in AVG patients.
Conclusions: The AngioJet™ system can be deemed an effective technique to
reestablish patency in occluded vascular access with minimal use of central venous
catheters for dialysis. Good technical and clinical success rates were achieved with
acceptable patency rates, especially in AVF patients.
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1 | INTRODUCTION
Adequate blood flow through hemodialysis arteriovenous (AV) access
is mandatory to perform hemodialysis and prevent thrombosis in
patients with end-stage renal disease. After creating arteriovenous fis-
tula (AVF) or arteriovenous graft (AVG), prospective monitoring is per-
formed to ensure functionality.1 Regular follow-up in a protocolized
surveillance program and aggressive treatment of access site stenosis
to maintain patency of vascular access seem to be of paramount
importance. Still, thrombosis of an AVF or AVG is not uncommon,
with a higher incidence in AVGs compared with AVFs. For native fis-
tulae, only one-third of the access events is observed compared with
grafts. In surveillance programs, fistula thrombosis should not exceed
0.25 episodes per patient year, in grafts this number should not
exceed 0.5.1 A variety of techniques have been described for the
treatment of vascular access thrombosis. Thrombus removal and
treatment of the underlying stenosis are the main goals in
reestablishing and maintaining patency.2–4 The outcomes of surgical
and endovascular intervention for vascular access thrombosis are
comparable.4 Surgical thrombectomy, pharmacological thrombolysis,
balloon-assisted thrombectomy, aspiration, mechanical
thrombectomy, or a combination of these techniques can be consid-
ered.5 Endovascular mechanical thrombectomy using the AngioJet™
Peripheral Thrombectomy system (Boston Scientific, Natick, MA) can
be deemed an effective technique, as described in a large multicenter
registry for treatment of deep vein thrombosis.6 Experience with this
system in occluded vascular access is relatively limited though, espe-
cially in native AVF, with varying clinical success and patency
rates.2–4,7–12 Moreover, the quality of the evidence fluctuates.13
The aim of this study was to review our 8-year experience in end-
ovascular mechanical thrombectomy using the AngioJet™ system in
patients with AVF and AVG, and to determine whether this can be
deemed an effective technique. Outcomes were technical and clinical
success and patency rates. Factors of influence on the patency after
the AngioJet™ procedure were also identified.
2 | MATERIALS AND METHODS
2.1 | Study design
Data collected in a database of patients with chronic renal dysfunc-
tion requiring hemodialysis were retrospectively analyzed. From April
2009 to December 2017, a total of 81 patients underwent either sur-
gical or endovascular interventions for occluded vascular access. Of
these patients, 65 were considered for endovascular mechanical
thrombectomy procedures with the AngioJet™ system for occlusion
of vascular access at our center; five patients were not treated; in
three patients the procedure was aborted due to local pain and chest
pain during the puncture procedure (these patients did not develop
myocardial infarction afterwards); and in two patients, endovascular
mechanical thrombectomy was not performed due to primary non-
function of the vascular access caused by an anastomotic problem.
The remaining 60 patients underwent endovascular thrombectomy
procedures with the AngioJet™ system and were included in this
study based on the per-protocol principles.
Approval of the Institutional Review Board was obtained (METc
2018/015). As retrospective patient file research does not fall under
the scope of the Dutch Medical Research Involving Human Subjects
Act, informed consent was not required. All patient-related data were
analyzed anonymously.
2.2 | Access creation
For the creation of a radiocephalic AVF, cephalic vein and radial artery
diameters of 2 mm were considered appropriate for fistula creation.
For the creation of brachiocephalic AVF and basilic vein transposition,
vein diameters and brachial artery diameters of 3 mm were consid-
ered appropriate for fistula creation. For AVG creation, a standard wall
PTFE graft (Gore-Tex, WL Gore & Associates, Flagstaff, Arizona) with
6 mm diameter and 0.5 mm wall thickness was used in a forearm loop
configuration, vein diameters of 4 mm were considered appropriate.
All anastomoses were created with a running polypropylene 6–0
suture (Prolene®, Ethicon Inc., Somerville, NJ).
2.3 | Indication for thrombectomy
In case of suspected vascular access thrombosis, patients were
referred to the emergency ward or the dialysis clinic to confirm the
diagnosis. Thrombosis was defined as a lack of thrill or pulse of the
vascular access on physical examination, confirmed by the absence of
flow on duplex ultrasound examination. Patients with proven access
thrombosis were admitted to the hospital and prepared for an inter-
vention with routine blood chemical analysis to determine serum
potassium. When serum potassium was within normal range
(3.5–5.0 mEq/L), patients were scheduled for an intervention as soon
as possible. For patients with elevated serum potassium levels, phar-
macological correction or dialysis was performed using a temporary
central venous catheter.
2.4 | Thrombectomy procedure
For endovascular mechanical thrombectomy, a 50-cm AngioJet™
AVX™ 6F or 90-cm Solent™ Proxi catheter was used (Boston Scien-
tific, Natick, MA). Systemic heparization was performed by adminis-
tering 50 IU/kg of heparin at the start of the procedure. No other
thrombolytic drugs or antibiotics were given. The Seldinger technique
was used to obtain access under ultrasound guidance. The puncture
location was determined by localization of the thrombus and type of
vascular access. A single 6F sheath was introduced, either proximal or
distal to the occlusion, and the occlusion was passed with a
0.035-in. wire. Thrombectomy was performed by retracting the
AngioJet™ catheter through the thrombus with a flow rate of 60 mL/
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min. A maximal run time of 300 s was used to prevent hemoglobinuria
due to hemolysis. The saline supply bag was heparinized with
2,500 IU of heparin. Complete angiography was performed and
remaining significant stenotic segments (>50%) were treated with bal-
loon angioplasty. In case of residual stenosis after balloon angioplasty,
a self-expanding nitinol stent was placed. In case of failed endo-
vascular treatment, additional surgical treatment was performed. Low-
dose acetylsalicylic acid was started in patients who did not receive
antiplatelet or anti-thrombotic drugs.
2.5 | Definitions
Technical success was defined as the restoration of blood flow, com-
bined with a residual stenosis of less than 30%, as reported by the
Society of Interventional Radiology.14 Clinical success was defined as
the completion of at least one hemodialysis session after treatment.1
Primary patency was defined as the interval from the time from the
first successful AngioJet™ procedure until any intervention designed to
maintain or reestablish patency, access thrombosis, or the time of mea-
surement of patency. Primary-assisted patency was defined as the inter-
val from the time from the first successful AngioJet™ procedure until
access thrombosis or the time of measurement of patency, including
intervening manipulations designed to maintain the functionality of a pat-
ent access. Secondary patency was defined as the time from the first suc-
cessful AngioJet™ procedure until access abandonment, thrombosis, or
the time of patency measurement including intervening manipulations
designed to reestablish functionality in thrombosed access.1
Stenosis was defined as the presence of a peak systolic velocity
greater than 310 cm/s in AVG and greater than 375 cm/s in AVF,
with a vessel diameter smaller than 2.0 mm.15 Indications for inter-
ventions were standardized; in patients with an AVF with flow rates
<500 ml/min and patients with an AVG with flow rates <600 ml/min,
or with a consistent monthly decrease of 25% or more with a flow
rate < 1,000 ml/min, angiography was scheduled and a percutaneous
transluminal angioplasty (PTA) was performed in the case of stenosis.1
2.6 | Follow-ups
All patients were monitored in the postprocedural period. Patients
were generally discharged the day after thrombectomy. After dis-
charge, routine physical examination and ultrasound dilution flow
measurements were performed with either a Transonic HD01 plus
Hemodialysis Monitor (Transonic Systems Inc., Ithaca, NY) or a
Fresenius 5008S CorDiax dialysis machine (Fresenius Medical Care,
Bad Homburg, Germany).
2.7 | Statistical analysis
Data are presented as means including standard error of the mean
(SEM) or medians including range. Differences in incidence rates
between groups were calculated with Pearson's chi-square test or
Fisher's exact test. Distribution was tested with the Kolmogorov–
Smirnov test. Differences between the groups were calculated
with the Mann–Whitney U test since data were skewed. Kaplan–
Meier survival analysis and the life table method were used to cal-
culate patency rates. The log-rank test was used to compare
patencies between the different procedures and to determine sig-
nificant factors of influence on survival. Following univariate anal-
ysis, all significant factors with a p value lower than 0.10 were
then entered into a multivariate Cox regression model with back-
ward elimination. The p values lower than 0.05 were considered




A total of 92 AngioJet™ procedures for vascular access thrombosis
were performed in 60 patients: 27 thrombectomies in occluded
AVFs and 65 in occluded AVGs. Characteristics are listed in
Table 1. Significant differences between groups were found in the
presence of diabetes mellitus (p = .026) and total follow-up time,
with 21.5 months in the AVF group and 11.9 months in the AVG
TABLE 1 Characteristics









Male 36 (55%) 20 (74%) .094
Female 7 (26%) 29 (45%)
BMI (kg m−2) 25.9 (5.2) 27.9 (9.0) .534
Diabetes mellitus 4 (15%) 25 (39%) .026*
Hypertension 21 (78%) 53 (82%) .679
Access type
Radiocephalic AVF 13 (48%) NA
Brachiocephalic AVF 10 (37%) NA
Basilic vein transposition 4 (15%) NA
Straight PTFE AVG NA 20 (31%)
PTFE loop AVG NA 45 (69%)
History of thrombosis 9 (33%) 32 (49%) .162
Time to AngioJet™ procedure
(day)
0.4 (0.6) 0.6 (1.3) .502





Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; BMI,
body mass index; NA, not applicable; PTFE, polytetrafluorethylene.
Note: Data are presented as numbers including percentages or means
including SDs; *p < .05.
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group (p = .04). Time from thrombosis to AngioJet™ procedure was
0.4 days in the AVF group and 0.6 days in the AVG
group (p = .502).
3.2 | AngioJet™ procedure
Results and specifications of AngioJet™ procedures are shown in
Table 2. Technical success was achieved in 92.6% of AVF cases and
92.0% of AVG cases (p = .963). Clinical success was achieved in
92.6% of AVF cases and 90.8% of AVG cases (p = .777). A peri-
procedural adjuvant intervention during the thrombectomy procedure
was performed in 92.6% of the AVF and 96.9% of the AVG cases
(p = .362). The types of additional interventions are shown in Table 2.
An additional PTA was most frequently performed at varying sites
(88.9% in the AVF group and 55.4% in the AVG group). Additional sur-
gical intervention due to residual stenosis or thrombosis was indicated
TABLE 2 Angiojet™ procedure specification












None 2 (7.4%) 2 (3.1%)
PTA arterial anastomosis NA 6 (9.2%)





Arterial stent 0 (0%) 0 (0%)





Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; NA,
not applicable; PTA, percutaneous transluminal angioplasty.
F IGURE 1 Primary patency rates of AVF and AVG after
AngioJet™ procedure. AVF, arteriovenous fistula; AVG, arteriovenous
graft [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Primary-assisted patency rates of AVF and AVG after
AngioJet™ procedure. AVF, arteriovenous fistula; AVG, arteriovenous
graft [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 3 Secondary patency rates of AVF and AVG after
AngioJet™ procedure. AVF, arteriovenous fistula; AVG, arteriovenous
graft [Color figure can be viewed at wileyonlinelibrary.com]
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in five cases (18.5%) in the AVF group and nine cases in the AVG
group (13.8%) (p = .391).
3.3 | Patency
Primary, primary-assisted, and secondary patency rates are shown in
Figures 1–3. A significantly higher primary patency rate after the
Angiojet™ system was found for the AVF group than for the AVG
group (p < .001). Also, primary-assisted patency was significantly
higher in the AVF group than in the AVG group (p = .001). Secondary
patency rates were comparable between the two groups (p = .262).
The results of univariate analysis of factors influencing patency are
shown in Table 3.
Use of immunosuppressive drugs was significantly associated
with primary patency and type of postoperative anticoagulant therapy
was significantly associated with primary assisted patency in AVF
patients. Types of preoperative and postoperative anticoagulant ther-
apy were significantly associated with secondary patency in AVF
patients. Type of postoperative anticoagulant therapy, time to proce-
dure, and side of vascular access were significantly associated with
primary patency in AVG patients. Sex, use of immunosuppressive
drugs, and type of preoperative and postoperative anticoagulant ther-
apy were significantly associated with secondary patency in AVG
patients.
Following univariate analysis, univariate factors with p < .10 were
entered into a multivariate Cox regression model. No significant
independent predictors for failure were found in AVF patients. Female
sex (HR 2.02, 95% CI 1.14–3.59, p = .016) and left-sided AVG
(HR 1.92, 95% CI 0.29–0.95, p = .032) were independent predictors
for failure in primary patency of AVG patients. Use of immunosup-
pressive drugs (HR 10.3, 95% CI 3.01–34.44, p < .001) and older age
(HR 5.91, 95% CI 1.92–18.22, p = .002) were independent predictors
for failure in secondary patency of AVG patients.
4 | DISCUSSION
This study shows that excellent technical and clinical success rates
can be achieved using the AngioJet™ pharmacomechanical
thrombectomy device in occluded vascular access with a short interval
from diagnosis to treatment. Promising patency rates were observed
during follow-up in both AVF and AVG patients. The AVF group did
display higher primary and primary-assisted patency rates. With
regard to the outcomes of the multivariate regression model,
decreased patency in female patients might be attributed to their usu-
ally smaller vessel diameter. Patency of left-sided vascular access was
not associated with left- or right-handedness of patients nor with the
use of central venous dialysis catheters. However, only five patients
were left-handed in the AVG group so this might not be representa-
tive. Age had been previously identified as predictor for survival,5 but
the use of immunosuppressive drugs had not. In our study, 12 patients
used immunosuppressive drugs in the AVG group and had a signifi-
cantly lower secondary patency rate than patients who did not use















Age 0.445 0.281 0.148 0.409 0.616 0.060*
BMI 0.983 0.542 0.663 0.434 0.625 0.269
Sex 0.217 0.780 0.947 0.010* 0.139 0.003*
Left- or right-handedness 0.555 0.685 0.413 0.377 0.234 0.659
Diabetes mellitus 0.576 0.151 0.098* 0.742 0.134 0.648
Hypertension 0.884 0.353 0.451 0.489 0.912 0.470
Immunosuppression therapy 0.041* 0.143 0.160 0.092* 0.221 0.005*
Preoperative anticoagulant
therapy
0.031* 0.001* 0.001* 0.353 0.880 0.004*
History of thrombosis 0.745 0.239 0.147 0.412 0.428 0.537
Time to procedure 0.350 0.282 0.386 0.012* 0.495 0.630
Type of access 0.553 0.203 0.156 0.419 0.075 0.188
Side of vascular access 0.679 0.906 0.822 0.032* 0.267 0.992
Postoperative anticoagulant
therapy
0.390 0.003* 0.003* 0.009* 0.623 0.010*
Additional PTA 0.728 0.493 0.383 0.868 0.609 0.240
Additional stent 0.671 0.370 0.370 0.880 0.969 0.327
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; BMI, body mass index; PTA, percutaneous transluminal angioplasty.
Note: p values are presented; *p < .10.
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them. The lower secondary patency rate might be attributed to the
negative effect of such drugs on these patients' vascular system.
In contrast to previous findings, the type of additional interven-
tion during the AngioJet™ procedure was not a predictor for survival.8
This might be attributed to an aggressive adjuvant periprocedural
treatment policy to ensure adequate outflow. Only two patients in
each group did not receive adjuvant periprocedural interventions.
It has also been suggested that long-term patency is dependent on
effective treatment of underlying stenosis and not on the
thrombectomy technique.9
Time to intervention was not a predictor for survival in our study
either in contrast to other findings.8 This might be explained by the
short interval between diagnosis and treatment, with a mean of
0.6 days for the AVG group and 0.4 days for the AVF group. This is
reflected in our data, where 92% of the patients were treated within
1 day of diagnosis and only four patients needed a central venous
catheter for dialysis. This short interval might be related to the inten-
sive follow-up scheme and logistic facilitations in our hospital that
help minimize treatment delay.
One of the first randomized multicenter studies to compare
AngioJet™ with surgical thrombectomy in patients with a thrombosed
AVG was performed by Vesely et al. in 1999. Technical success rates
and patency rates were lower than previously reported studies with
other interventions and lower than that indicated by the 2006 KDOQI
guidelines.1,2 Still, this study was the first to define success as effec-
tive completion of at least one hemodialysis session and to report
standardized patency rates. The outcomes might be hampered by the
use of an older AngioJet™ system with lower power and lacking a
standardized treatment protocol and expertise. More recent studies,
including ours, were conducted with the newer, more powerful,
AngioJet™ AVX system and show improved results, reporting clinical
success rates of up to 97%.3,8,9,11,12,16
Kakkos et al. reported their results in the largest population to
date. AngioJet™ thrombectomy was performed in 261 AVG cases and
24 AVF cases. Clinical success rate was 95%, which was comparable
to our findings. Three-month functional primary patency rate of 55%
was comparable to our patency rate in the AVG group. A relatively
small number of patients with AVF access thrombosis were included
and compared with the AVG group, and success rates were not speci-
fied for AVF patients.8 Experience and comparison of different endo-
vascular thrombectomy devices in AVF is described by Yang et al.9
The AngioJet™ thrombectomy device was compared with the Arrow-
Trerotola™ percutaneous thrombectomy device (PTD) in
275 thrombectomy procedures in patients with occluded AVF. They
concluded that the PTD had a significantly higher success rate than
the AngioJet™, 91% versus 76% (p = .002), with analogous patency
rates. Our clinical success rate with the AngioJet™ did resemble the
clinical success rate of the PTD group in their study; the patency rates
were likewise similar. This might be explained by the type of
AngioJet™ catheter, as only 31 of the 134 procedures were per-
formed with the latest, more powerful AVX catheter.
A recent systematic review compared the outcomes of different
endovascular devices in percutaneous treatment of thrombosed
vascular access, mainly divided into two categories: thrombectomy
dependent and thrombolysis dependent. No significant differences
were found in vascular access survival between the different treat-
ments. However, a shift toward thrombectomy-dependent devices to
reduce the amount of hemorrhagic complications associated with
thrombolytic drugs was observed over time.5
The strength of this study is that we provide detailed information
about the procedures and outcomes with the latest AngioJet™ system,
especially in occluded AVFs. Patency rates were compared between
AVF and AVG groups and multivariable analysis was performed to
define predictors for failure after treatment. Limitations of the current
study are its retrospective nature and the fact that the total number of
included AVFs was relatively small compared with the included AVGs.
5 | CONCLUSIONS
Based on the results of our retrospective study, the AngioJet™ system
can be deemed an effective technique to reestablish patency in
occluded vascular access, with minimal use of central venous cathe-
ters for dialysis. Good technical and clinical success rates were
achieved with acceptable patency rates, which improved in patients
with an AVF compared with patients with an AVG. Furthermore, this
study identified several factors that influenced patency after the
AngioJet™ thrombectomy procedure.
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